---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-010951"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2022-03-18T23:59:59+00:00"
generated_at: "2026-06-26T21:42:01.752074+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Aeglea Bio's VP/Controller Steven Weber resigns; CFO Alspaugh named principal accounting officer

## Summary
- Steven Weber resigns as VP/Corporate Controller and principal accounting officer, effective March 25, 2022.
- CFO Jonathan Alspaugh appointed principal accounting officer effective March 17, 2022.
- Alspaugh, age 39, has served as CFO since July 2021; prior roles include Managing Director at Evercore.

## SEC filing metadata
- accession: 0001564590-22-010951
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2022-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/0001564590-22-010951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/agle-8k_20220316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-010951
- JSON: https://secwatch.observer/filing/0001564590-22-010951.json
- Plain text: https://secwatch.observer/filing/0001564590-22-010951.txt

## Key facts
- Executive change
  Steven Weber resigned as Vice President and Corporate Controller at Spyre Therapeutics, Inc..
  - Action: resigned
  - Role: Vice President and Corporate Controller
  source text: On March 16, 2022, Steven Weber, the Vice President and Corporate Controller of Aeglea Biotherapeutics, Inc. (the “Company”), and the Company’s principal accounting officer, notified the Company that he will be resigning from his positions, effective March 25, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/0001564590-22-010951-index.htm
- Executive change
  Jonathan Alspaugh was appointed as Principal Accounting Officer at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: On March 17, 2022, the Company appointed Jonathan Alspaugh, age 39, Chief Financial Officer, as its principal accounting officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/0001564590-22-010951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.